{
    "2019-10-23": [
        [
            {
                "time": "",
                "original_text": "智飞生物(300122.SZ)：Q3增长显著，在研管线充沛",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "Q3",
                        "增长显著",
                        "在研管线"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "智飞生物：在研产品稳步推进 增持评级",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "在研产品",
                        "稳步推进",
                        "增持评级"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "智飞生物业绩大涨难掩成本激增 5亿元增资全资子公司",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "业绩大涨",
                        "成本激增",
                        "5亿元",
                        "增资",
                        "全资子公司"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "mixed",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【民生医药|季报点评】智飞生物：预计HPV系列大幅增长，在研管线稳步推进，自主产品线有望逐步丰富",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "HPV系列",
                        "大幅增长",
                        "在研管线",
                        "稳步推进",
                        "自主产品线",
                        "逐步丰富"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}